Please use this identifier to cite or link to this item: https://doi.org/10.3892/ijo-00000465
Title: The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells
Authors: Ling, L.-U.
Lin, H.
Tan, K.-B.
Chiu, G.N.C. 
Keywords: Colon cancer
Drug combination
Irinotecan
Protein kinase C
Safingol
Synergism
Issue Date: Dec-2009
Source: Ling, L.-U., Lin, H., Tan, K.-B., Chiu, G.N.C. (2009-12). The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. International Journal of Oncology 35 (6) : 1463-1471. ScholarBank@NUS Repository. https://doi.org/10.3892/ijo-00000465
Abstract: Colon cancer represents one of the most common solid tumors in adults. Although 5-fluorouracil (5-FU) and irinotecan have been frequently administered in colon cancer patients, low response rates to these single drug therapies were reported. It is therefore imperative to search for new targeted combination therapies that are effective. In this study, we investigated the anti-cancer effect of safingol as a single agent or in combination with irinotecan using HT-29 and LS-174T colon cancer cells as our in vitro models. As a single agent, safingol was more potent than irinotecan and 5-FU, with IC50 values of 2.5±1.1 μM and 3.4±1.0 μM achieved in HT-29 and LS-174T cells, respectively. However, protein kinase C (PKC) was not inhibited with concentrations of safingol which could induce substantial cell kill. The combination of safingol/irinotecan at 1:1 molar ratio was found to be additive in HT-29 cells (CI=0.94) and synergistic in LS-174T cells (CI=0.68), and resulted in concentration- and time-dependent down-regulation of p-PKC and p-MARCKS. The drug effect of the safingol/irinotecan combination was further modulated in the presence of a PKC stimulator (phorbol 12-myristate 13-acetate) or a PKC inhibitor (staurosporine). Furthermore, the 1:1 safingol/irinotecan combination inhibited the adhesion of colon cancer cells to the extracellular matrix 4-h post-treatment. Taken together, modulation of the PKC pathway could be a possible molecular basis for the observed synergism of the safingol/irinotecan combination, and these results demonstrate the therapeutic potential of this drug combination in colon cancer treatment.
Source Title: International Journal of Oncology
URI: http://scholarbank.nus.edu.sg/handle/10635/106449
ISSN: 10196439
DOI: 10.3892/ijo-00000465
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

1
checked on Feb 15, 2018

WEB OF SCIENCETM
Citations

1
checked on Jan 30, 2018

Page view(s)

32
checked on Feb 19, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.